



EYLEA HD[®]
(aflibercept) Injection 8 mg

EYLEA HD[®] (aflibercept) Injection

Payer Coverage as of 08/18/2025

National and Regional Payers

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA[®] (aflibercept) Injection.

EYLEA HD, EYLEA, and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

© 2024, Regeneron Pharmaceuticals, Inc. All rights reserved. US.EHD.24.11.0001 11/2024

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA

INDICATIONS

EYLEA HD® (aflibercept) Injection 8 mg is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

EYLEA® (aflibercept) Injection 2 mg is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- EYLEA HD and EYLEA are contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA HD or EYLEA.

WARNINGS AND PRECAUTIONS

- Intravitreal injections, including those with aflibercept, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering EYLEA HD or EYLEA. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA HD and EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD and EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- EYLEA HD: The incidence of reported thromboembolic events in the wet AMD study (PULSAR) from baseline through week 48 was 0.4% (3 out of 673) in the combined group of patients treated with EYLEA HD compared with 1.5% (5 out of 336) in patients treated with EYLEA 2 mg. The incidence in the DME study (PHOTON) from baseline to week 48 was 3.1% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 3.6% (6 out of 167) in patients treated with EYLEA 2 mg.
- EYLEA: The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.

ADVERSE EFFECTS

- EYLEA HD:
 - The most common adverse reactions ($\geq 3\%$) reported in patients receiving EYLEA HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters, vitreous detachment, corneal epithelium defect, and retinal hemorrhage.
- EYLEA:
 - Serious adverse reactions related to the injection procedure have occurred in $<0.1\%$ of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
 - The most common adverse reactions ($\geq 5\%$) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
- Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA HD or EYLEA and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Please see Important Safety Information throughout and full Prescribing Information for **EYLEA HD** and **EYLEA®** (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

MACs

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
Palmetto GBA - Jurisdiction JJ	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Palmetto GBA - Jurisdiction JM	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Novitas Solutions - Jurisdiction JH	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Novitas Solutions - Jurisdiction JL	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Nat'l Gov't Serv. (NGS) - Jurisdiction JK	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Nat'l Gov't Serv. (NGS) – Jurisdiction J6	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Wisc. Phys Serv. (WPS) - Jurisdiction J5	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Wisc. Phys Serv. (WPS) - Jurisdiction J8	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Celerian Group Co. (CGS) - Jurisdiction J15	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
First Coast Service Options (FCSO) - Jurisdiction FL	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Noridian Healthcare Solutions - Jurisdiction JE	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A
Noridian Healthcare Solutions - Jurisdiction JF	Medicare	Wet AMD, DME, DR	First-line access, no step edit	12/12/2024	N/A

*For plans with step therapy requirements, review your patient’s Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

National Payers

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
UnitedHealthcare	Commercial	Wet AMD, DME, DR	First-line access, no step edit	01/01/2025	Link
	Medicare Advantage	DME, DR	First-line access, no step edit	04/01/2025	Link
		Wet AMD	Single agent step through 3 consecutive monthly bevacizumab injections		
Humana	Commercial and Medicare Advantage	Wet AMD, DME, DR	Single agent step through bevacizumab	07/01/2025	Link
Anthem BCBS (Elevance Health)	Commercial, Medicare Advantage, and Managed Medicaid	Wet AMD, DME, DR	First-line access, no step edit	06/12/2025	Link
Aetna	Medicare Advantage	Wet AMD	Single agent step through bevacizumab	07/01/2025	Link
		DME, DR	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab if 20/50 or better		
	Commercial	Wet AMD, DME, DR	Double agent step through bevacizumab and ranibizumab-nuna or ranibizumab-eqrn	07/14/2025	Link
BCBS Federal Employee Program	Commercial	Wet AMD, DME, DR	First-line access, no step edit	01/01/2024	Link
Cigna	Commercial and Medicare Advantage	Wet AMD, DME, DR	20/50 or worse vision for DME - first-line access, no step edit required Single agent step through bevacizumab	03/15/25	Link
Department of Veterans Affairs (VA)	Veterans Affair	Wet AMD, DME, DR	First-line access, no step edit	01/01/2025	N/A
Department of Defense (DOD)	Government	Wet AMD, DME, DR	First-line access, no step edit	11/01/2023	N/A

*For plans with step therapy requirements, review your patient’s Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

Regional Payers (listed alphabetically)

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
BCBS of Alabama	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	09/05/2024	Link
BCBS of Arkansas	Commercial	Wet AMD, DME, DR	First-line access, no step edit	01/01/2025	Link
Blue Shield of California	Commercial and Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	04/03/2025	Link
BCBS of Illinois (HCSC)	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	01/01/2025	Link
	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	05/15/2025	Link
BCBS of Kansas City	Commercial	Wet AMD, DME, DR	First-line access, no step edit	01/01/2024	N/A
BCBS of Kansas	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	08/02/2024	N/A
	Commercial		Double agent step through bevacizumab and ranibizumab-nuna or ranibizumab-eqrn or ranibizumab	02/01/2025	Link
BCBS of Louisiana	Commercial and Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	03/10/2025	N/A
BCBS of Massachusetts	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	03/01/2025	Link
	Medicare Advantage		Double agent step through bevacizumab and ranibizumab-nuna or ranibizumab-eqrn or faricimab-svoa or brolucizumab-dbll	04/01/2025	Link

*For plans with step therapy requirements, review your patient’s Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

Regional Payers (listed alphabetically)

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
BCBS of Michigan	Commercial and Medicare Advantage	DME	20/50 or worse vision - first-line access, no step edit required Single agent step through bevacizumab	10/03/2024	Link
		Wet AMD, DR	Single agent step through bevacizumab		
BCBS of Minnesota	Commercial and Medicare Advantage	Wet AMD, DME, DR	Single agent step through bevacizumab	02/05/2024	Link
BCBS of Mississippi	Commercial	Wet AMD, DME, DR	Double agent step through bevacizumab and ranibizumab or ranibizumab-nuna or ranibizumab-eqrn	03/27/2025	Link
BCBS of Montana (HCSC)	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	05/01/2024	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	01/01/2024	Link
BCBS of Nebraska	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	11/06/2024	Link
BCBS of New Mexico (HCSC)	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	05/01/2024	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	01/01/2024	Link
BCBS of North Carolina	Commercial, Medicare Advantage, and Managed Medicaid	Wet AMD, DME, DR	Single agent step through bevacizumab	01/01/2025	Link
BCBS of North Dakota	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	09/05/2024	Link
	Medicare Advantage	Wet AMD, DME, DR		10/03/2024	Link
		DME	20/50 or worse vision - first-line access, no step required		

*For plans with step therapy requirements, review your patient’s Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

Regional Payers (listed alphabetically)

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
BCBS of Oklahoma (HCSC)	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	05/01/2024	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	01/01/2024	Link
BCBS of Rhode Island	Commercial	Wet AMD, DME, DR	See policy	07/01/2025	Link
BCBS of South Carolina	Commercial and Medicare Advantage	Wet AMD, DME, DR	Double agent step through ranibizumab, faricimab and/or ranibizumab biosimilar	03/01/2025	Link
BCBS of Tennessee	Commercial and Medicare Advantage	Wet AMD	Single agent step through bevacizumab	03/04/2025	Link
		DME, DR	Single agent step through bevacizumab or ranibizumab		
BCBS of Texas (HCSC)	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	05/15/2024	Link
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	01/01/2024	Link
Capital Blue Cross	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	09/05/2024	Link
CareFirst BCBS	Commercial and Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	03/01/2025	Link
Centene	Commercial and Managed Medicaid	DME	20/50 or worse vision - first-line access, no step edit required	02/01/2025	Link
		Wet AMD, DME, DR	Single agent step through bevacizumab		
EmblemHealth/ConnectiCare	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	05/01/2025	Link
	Commercial and Managed Medicaid	Wet AMD, DME, DR	Single agent step through bevacizumab	05/30/2025	

*For plans with step therapy requirements, review your patient’s Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for **EYLEA HD** and **EYLEA®** (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

Regional Payers (listed alphabetically)

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
Florida Blue	Commercial	Wet AMD, DME, DR	First-line access, no step edit	08/15/2025	Link
	Medicare Advantage	Wet AMD, DME, DR	Single agent step through bevacizumab	07/15/2025	Link
Geisinger	Commercial and Medicare Advantage	Wet AMD, DME, DR	See policy	03/11/2025	Link
Hawaii Medical Service Association (HMSA)	Commercial and Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	05/22/2025	Link
HealthPartners	Commercial and Medicare Advantage	Wet AMD, DME, DR	Single agent step through bevacizumab	07/01/2025	Link
Highmark BCBS	Commercial and Medicare Advantage	DME, DR	First-line access, no step edit	04/01/2024	Link
		Wet AMD	Single agent step through 3 consecutive monthly bevacizumab injections		
Horizon BCBS of NJ	Commercial, Medicare Advantage, and Managed Medicaid	Wet AMD, DME, DR	See policy	07/25/2025	Link
Independence Blue Cross	Commercial and Medicare Advantage	Wet AMD, DME, DR	Double agent step through bevacizumab and ranibizumab or ranibizumab-nuna	01/01/2025	Link
Independent Health	Medicare Advantage	Wet AMD, DME, DR	Single agent step through bevacizumab	12/01/2023	Link
Lifetime (Excellus)	Commercial and Medicare Advantage	Wet AMD, DME, DR	Double agent step through 3 consecutive monthly bevacizumab injections and 1 EYLEA injection	07/17/2025	Link
		DME, DR	20/50 or worse vision - first-line access, no step edit required		

*For plans with step therapy requirements, review your patient’s Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

Regional Payers (listed alphabetically)

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
Mass General Brigham Health	Commercial	Wet AMD	Double agent step through bevacizumab and ranibizumab-nuna	11/01/2023	Link
		DME, DR	Single agent step through bevacizumab		
Medica	Commercial and Medicare Advantage	Wet AMD, DME, DR	Single agent step through 3 consecutive monthly bevacizumab injections	09/15/2023	Link
Medical Mutual of Ohio	Commercial and Medicare Advantage	Wet AMD, DME, DR	Double agent step through bevacizumab and EYLEA	07/17/2024	Link
Moda Health	Commercial and Medicare Advantage	Wet AMD, DME, DR	Single agent step through bevacizumab	09/05/2023	Link
Oscar	Commercial	Wet AMD, DME, DR	Double agent step through bevacizumab and EYLEA	12/19/2024	Link
Point32Health (Tufts and Harvard Pilgrim)	Commercial	Wet AMD, DME, DR	Double agent step through 3 consecutive monthly bevacizumab injections and 1 EYLEA injection or ranibizumab	07/01/2025	Link
	Medicare Advantage				Link
Premiera Blue Cross	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab	04/01/2025	Link
Priority Health	Commercial	Wet AMD, DME, DR	Single agent step through 3 consecutive monthly bevacizumab injections	04/01/2025	Link
		DME	20/50 or worse vision - first-line access, no step edit required		
	Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit		
Providence Health Plan (OR, WA, and CA)	Commercial and Medicare Advantage	Wet AMD, DME, DR	See policy	04/01/2025	Link
Regence	Commercial and Medicare Advantage	Wet AMD, DME, DR	Double agent step through bevacizumab and ranibizumab biosimilar	05/15/2025	Link

*For plans with step therapy requirements, review your patient's Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.



EYLEA HD Payer Coverage as of 08/18/2025

Regional Payers (listed alphabetically)

Health Plan*	Channel	Indication(s)	Status†	Effective Date	Policy Link
Sentara Health Plan	Commercial and Medicare Advantage	Wet AMD, DME, DR	Double agent step through bevacizumab and EYLEA	04/15/2025	Link
UCare Minnesota	Medicare Advantage	Wet AMD, DME, DR	Single agent step through bevacizumab	01/06/2023	Link
		DME, DR	20/50 or worse vision - first-line access, no step edit required		
UPMC	Commercial and Medicare Advantage	Wet AMD, DME, DR	First-line access, no step edit	08/01/2025	Link
Wellmark	Commercial	Wet AMD, DME, DR	Single agent step through bevacizumab or ranibizumab-nuna or ranibizumab or faricimab-svoa	08/18/2025	Link
	Medicare Advantage		Single agent step through bevacizumab	08/08/2024	Link
		DME	20/50 or worse vision - first-line access, no step edit required		

*For plans with step therapy requirements, review your patient’s Summary of Benefits for specific criteria.

†Prior authorization may still be required.

AMD = age-related macular degeneration; DME = diabetic macular edema; DR = diabetic retinopathy.

All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of April 2024.

Individual plan policies may vary, and the information presented herein does not replace a benefit verification.

Enroll your eligible patients in EYLEA4U®, the patient support program for EYLEA HD. EYLEA4U offers benefit verification support and can provide your office with a Summary of Benefits summarizing patient coverage, prior authorization, and cost share.

Please see Important Safety Information throughout and full Prescribing Information for EYLEA HD and EYLEA® (aflibercept) Injection.

